Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib, Nivolumab, and Ipilimumab in Poorly Differentiated Neuroendocrine Carcinomas
NCT04079712Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabozantinib in neuroendocrine carcinoma (NEC), sponsored by National Cancer Institute. Started Aug 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04079712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079712.